Cargando…
Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation
Monoamine oxidase (MAO) activity is reduced in cigarette smokers and this may promote the reinforcing actions of nicotine, thereby enhancing the addictive properties of cigarettes. At present, it is unclear how cigarette smoking leads to MAO inhibition, but preclinical studies in rodents show that M...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424897/ https://www.ncbi.nlm.nih.gov/pubmed/36051642 http://dx.doi.org/10.3389/fnins.2022.886496 |
_version_ | 1784778326858006528 |
---|---|
author | Sved, Alan F. Weeks, Jillian J. Grace, Anthony A. Smith, Tracy T. Donny, Eric C. |
author_facet | Sved, Alan F. Weeks, Jillian J. Grace, Anthony A. Smith, Tracy T. Donny, Eric C. |
author_sort | Sved, Alan F. |
collection | PubMed |
description | Monoamine oxidase (MAO) activity is reduced in cigarette smokers and this may promote the reinforcing actions of nicotine, thereby enhancing the addictive properties of cigarettes. At present, it is unclear how cigarette smoking leads to MAO inhibition, but preclinical studies in rodents show that MAO inhibition increases nicotine self-administration, especially at low doses of nicotine. This effect of MAO inhibition develops slowly, likely due to plasticity of brain monoamine systems; studies relying on acute MAO inhibition are unlikely to replicate what happens with smoking. Given that MAO inhibition may reduce the threshold level at which nicotine becomes reinforcing, it is important to consider this in the context of very low nicotine content (VLNC) cigarettes and potential tobacco product regulation. It is also important to consider how this interaction between MAO inhibition and the reinforcing actions of nicotine may be modified in populations that are particularly vulnerable to nicotine dependence. In the context of these issues, we show that the MAO-inhibiting action of cigarette smoke extract (CSE) is similar in VLNC cigarettes and cigarettes with a standard nicotine content. In addition, we present evidence that in a rodent model of schizophrenia the effect of MAO inhibition to enhance nicotine self-administration is absent, and speculate how this may relate to brain serotonin systems. These issues are relevant to the MAO-inhibiting effect of cigarette smoking and its implications to tobacco product regulation. |
format | Online Article Text |
id | pubmed-9424897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94248972022-08-31 Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation Sved, Alan F. Weeks, Jillian J. Grace, Anthony A. Smith, Tracy T. Donny, Eric C. Front Neurosci Neuroscience Monoamine oxidase (MAO) activity is reduced in cigarette smokers and this may promote the reinforcing actions of nicotine, thereby enhancing the addictive properties of cigarettes. At present, it is unclear how cigarette smoking leads to MAO inhibition, but preclinical studies in rodents show that MAO inhibition increases nicotine self-administration, especially at low doses of nicotine. This effect of MAO inhibition develops slowly, likely due to plasticity of brain monoamine systems; studies relying on acute MAO inhibition are unlikely to replicate what happens with smoking. Given that MAO inhibition may reduce the threshold level at which nicotine becomes reinforcing, it is important to consider this in the context of very low nicotine content (VLNC) cigarettes and potential tobacco product regulation. It is also important to consider how this interaction between MAO inhibition and the reinforcing actions of nicotine may be modified in populations that are particularly vulnerable to nicotine dependence. In the context of these issues, we show that the MAO-inhibiting action of cigarette smoke extract (CSE) is similar in VLNC cigarettes and cigarettes with a standard nicotine content. In addition, we present evidence that in a rodent model of schizophrenia the effect of MAO inhibition to enhance nicotine self-administration is absent, and speculate how this may relate to brain serotonin systems. These issues are relevant to the MAO-inhibiting effect of cigarette smoking and its implications to tobacco product regulation. Frontiers Media S.A. 2022-08-16 /pmc/articles/PMC9424897/ /pubmed/36051642 http://dx.doi.org/10.3389/fnins.2022.886496 Text en Copyright © 2022 Sved, Weeks, Grace, Smith and Donny. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Sved, Alan F. Weeks, Jillian J. Grace, Anthony A. Smith, Tracy T. Donny, Eric C. Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title | Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title_full | Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title_fullStr | Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title_full_unstemmed | Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title_short | Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation |
title_sort | monoamine oxidase inhibition in cigarette smokers: from preclinical studies to tobacco product regulation |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424897/ https://www.ncbi.nlm.nih.gov/pubmed/36051642 http://dx.doi.org/10.3389/fnins.2022.886496 |
work_keys_str_mv | AT svedalanf monoamineoxidaseinhibitionincigarettesmokersfrompreclinicalstudiestotobaccoproductregulation AT weeksjillianj monoamineoxidaseinhibitionincigarettesmokersfrompreclinicalstudiestotobaccoproductregulation AT graceanthonya monoamineoxidaseinhibitionincigarettesmokersfrompreclinicalstudiestotobaccoproductregulation AT smithtracyt monoamineoxidaseinhibitionincigarettesmokersfrompreclinicalstudiestotobaccoproductregulation AT donnyericc monoamineoxidaseinhibitionincigarettesmokersfrompreclinicalstudiestotobaccoproductregulation |